门冬氨酸钾镁治疗轻度高血压病临床观察

目的：前瞻性研究低剂量镁制剂降压的临床效应。方法：选择我院门诊轻度高血压患者60例（按WHO／ISB标准），无靶器官损害和继发性高血压为入选对象。配对随机分为治疗组（n＝30）与对照组（n＝30）。治疗组口服门冬氨酸钾镁，同时接受行为干预，对照组只接受行为干预，疗程3月。结果：治疗组收缩压（SBP）由157±7mmHg降至146±8mmHg（p＜0．05），舒张压（DBP）由101±5mmHg降至92±7mmHg（P＜0．05）。对照组SBP由156±6mmHg降至148±5mmHg（P＜0．05），DBP由100±4mmHg降至96±8mmHg（P＞0．05）。治疗组显效率33．33％，总有效率83．33％。对照组显效率6．66％，总有效率33．3％，治疗组与对照组疗效比较差异非常显著（P＜0．01），结论：门冬氨酸钾镁可用于治疗轻度高血压病．也可用于中重度高血压的辅助治疗。

CLINICAL OBSERVATION OF TREATMENT OF MILD HYPERTENSION POTASSIUM-MAGNESSIUM ASPARTATE

Objective: To investigate the therapeutic effect of low dose Magnessium on mild hypertension - Method: Sixty cases of mild hypertension were divided randomly into two groups. The therapeutic group (n=30) was treated with potassium-magnessium aspartate and behavioral intervention for three months. In the control group(n = 30), only behavioral intervention was used. Results: The markedly effective rate and total effective rate were 33. 33% and 83. 33% respectively in the therapeutic group. In the control group. the markedly effective rate and total effective rate were 6. 66% and 33. 33% respectively, There was significant difference between the two groups. Conclusion: The results suggested that potassium - magnessium aspartete can reduce blood pressure of hypertensive patients. It can be used to treat mild hypertension and as an adjuvant treatment for the moderate-Severe hypertension.